65. Primary immunodeficiency Clinical trials / Disease details
Clinical trials : 500 / Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-002491-24-DE (EUCTR) | 11/05/2016 | 30/03/2016 | Safety of Abatacept in patients with interstitial lung disease and common variable immunodeficiency (CVID) and related disease | Safety of Abatacept in patients with interstitial lung disease and common variable immunodeficiency (CVID) and related disease - SAIL | CVID patients confirmed according to ESID/PAGID criteria or related disorders which fulfill the diagnostic criteria for CVID and interstitial lung disease or granuloma diagnosed by chest CT positive for nodules, lines or ground-glass signs MedDRA version: 18.1;Level: PT;Classification code 10022611;Term: Interstitial lung disease;System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disorders MedDRA version: 18.1;Classification code 10021449;Term: Immunodeficiency common variable;System Organ Class: 10021428 - Immune system disorders;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: ORENCIA® 125 mg solution for injection in pre-filled syringe Product Name: Abatacept Product Code: BMS-188667 | Universitätsklinikum Freiburg, vertreten durch den Leitenden Ärztlichen Direktor | NULL | Not Recruiting | Female: yes Male: yes | 10 | Phase 2 | Germany | ||
| 2 | EUCTR2008-003368-21-IT (EUCTR) | 04/06/2008 | 06/02/2009 | Pilot trial of CTLA4-Ig (Abatacept) in a child affected by a severe congenital autoimmune syndrome (IPEX) - Trial of Abatacept in IPEX syndrome | Pilot trial of CTLA4-Ig (Abatacept) in a child affected by a severe congenital autoimmune syndrome (IPEX) - Trial of Abatacept in IPEX syndrome | For patients with a stabilized clinical condition, not recovered in care units for acute problems. MedDRA version: 9.1;Level: HLGT;Classification code 10003816 MedDRA version: 9.1;Level: HLT;Classification code 10027657 | Trade Name: ORENCIA INN or Proposed INN: ABATACEPT | ISTITUTO PER L`INFANZIA BURLO GAROFOLO | NULL | Not Recruiting | Female: no Male: yes | Italy |